[1]
‘Diagnosis and management of type 1 diabetes in children, young people and adults | Guidance and guidelines | NICE’ [Online]. Available: https://www.nice.org.uk/guidance/cg15
[2]
‘Type 2 diabetes in adults: management | Guidance and guidelines | NICE’ [Online]. Available: https://www.nice.org.uk/guidance/ng28
[3]
‘Efficacy and Safety of Glucagon-like peptide-1 receptor agonists in type 2 diabetes Systematic review and mixed-treatment comparison analysis’ [Online]. Available: http://onlinelibrary.wiley.com.ezproxy3.lib.le.ac.uk/doi/10.1111/dom.12849/epdf
[4]
‘Obesity: identification, assessment and management | Guidance and guidelines | NICE’ [Online]. Available: https://www.nice.org.uk/guidance/cg189
[5]
‘Managing Older People with Type 2 Diabetes: IDF Global Guideline - International Federation on Ageing’. [Online]. Available: https://www.ifa-fiv.org/managing-older-people-with-type-2-diabetes-idf-global-guideline/
[6]
‘NHS Evidence: an introduction’. [Online]. Available: http://www.solent.nhs.uk/_store/documents/nhs_evidence_guide.pdf
[7]
R. I. G. Holt, C. Cockram, A. Flyvbjerg, and B. J. Goldstein, Textbook of Diabetes, 5th ed. Somerset: John Wiley & Sons, Incorporated, 2016 [Online]. Available: http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056
[8]
R. I. G. Holt, Textbook of diabetes, 4th ed. Chichester: Wiley-Blackwell, 2010 [Online]. Available: http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=269077
[9]
M. A. Atkinson, ‘The Pathogenesis and Natural History of Type 1 Diabetes’, Cold Spring Harbor Perspectives in Medicine, vol. 2, no. 11, pp. a007641–a007641, Nov. 2012, doi: 10.1101/cshperspect.a007641.
[10]
H. F. Jelinek, A. Stranieri, A. Yatsko, and S. Venkatraman, ‘Data analytics identify glycated haemoglobin co-markers for type 2 diabetes mellitus diagnosis’, Computers in Biology and Medicine, vol. 75, pp. 90–97, Aug. 2016, doi: 10.1016/j.compbiomed.2016.05.005.
[11]
S M Attard, ‘Implications of iron deficiency/anemia on the classification of diabetes using HbA1c’, Nutrition & Diabetes, vol. 5, no. 6, 2015, doi: doi: 10.1038/nutd.2015.16. [Online]. Available: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4491857/
[12]
V. T. Samuel and G. I. Shulman, ‘Intergrating Mechanisms for Insulin Resistance: Common Threads and Missing Links’, Cell, vol. 148, no. 5, pp. 852–871, Mar. 2012, doi: 10.1016/j.cell.2012.02.017.
[13]
Beverley M Shields, ‘Can clinical features be used to differentiate type 1 from type 2 diabetes? A systematic review of the literature’, BMJ Open, vol. 5, no. 11, 2015, doi: doi: 10.1136/bmjopen-2015-009088. [Online]. Available: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4636628/?report=classic
[14]
F. Zaccardi, D. R. Webb, T. Yates, and M. J. Davies, ‘Pathophysiology of type 1 and type 2 diabetes mellitus: a 90-year perspective’, Postgraduate Medical Journal, vol. 92, no. 1084, pp. 63–69, Feb. 2016, doi: 10.1136/postgradmedj-2015-133281.
[15]
Anthony H. Barnett, Jenny Grice, New Mechanisms in Glucose Control. BMJ Books; 1 edition, 2013 [Online]. Available: http://ezproxy.lib.le.ac.uk/login?url=http://lib.myilibrary.com?id=478133
[16]
E. W. Gregg, ‘The Changing Tides of the Type 2 Diabetes Epidemic—Smooth Sailing or Troubled Waters Ahead? Kelly West Award Lecture 2016’, Diabetes Care, Aug. 2017, doi: 10.2337/dci16-0055.
[17]
R. I. G. Holt, C. Cockram, A. Flyvbjerg, and B. J. Goldstein, Textbook of Diabetes, 5th ed. Somerset: John Wiley & Sons, Incorporated, 2016 [Online]. Available: http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056
[18]
R. I. G. Holt, Textbook of diabetes, 4th ed. Chichester: Wiley-Blackwell, 2010 [Online]. Available: http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=269077
[19]
K. C. Copeland et al., ‘Management of Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) in Children and Adolescents’, PEDIATRICS, vol. 131, no. 2, pp. 364–382, Feb. 2013, doi: 10.1542/peds.2012-3494.
[20]
Kenneth Hodson, ‘Gestational diabetes: emerging concepts in pathophysiology’, Obstetric Medicine, vol. 3, no. 4, 2010, doi: doi: 10.1258/om.2010.100025. [Online]. Available: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4989628/?report=classic
[21]
Latika Sahu, ‘Comparison of the American Diabetes Association and World Health Organization criteria for gestational diabetes mellitus and the outcomes of pregnancy’, Obstetric Medicine, vol. 2, no. 4, 2009, doi: doi: 10.1258/om.2009.080049. [Online]. Available: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4989660/?report=classic
[22]
S. S. Schwartz, S. Epstein, B. E. Corkey, S. F. A. Grant, J. R. Gavin, and R. B. Aguilar, ‘The Time Is Right for a New Classification System for Diabetes: Rationale and Implications of the β-Cell–Centric Classification Schema’, Diabetes Care, vol. 39, no. 2, pp. 179–186, Feb. 2016, doi: 10.2337/dc15-1585.
[23]
C. J. Nolan, N. B. Ruderman, S. E. Kahn, O. Pedersen, and M. Prentki, ‘Insulin Resistance as a Physiological Defense Against Metabolic Stress: Implications for the Management of Subsets of Type 2 Diabetes’, Diabetes, vol. 64, no. 3, pp. 673–686, Mar. 2015, doi: 10.2337/db14-0694.
[24]
E. A. Gale, ‘Is type 2 diabetes a category error?’, The Lancet, vol. 381, no. 9881, pp. 1956–1957, Jun. 2013, doi: 10.1016/S0140-6736(12)62207-7.
[25]
C. Moreno-Castilla, D. Mauricio, and M. Hernandez, ‘Role of Medical Nutrition Therapy in the Management of Gestational Diabetes Mellitus’, Current Diabetes Reports, vol. 16, no. 4, Apr. 2016, doi: 10.1007/s11892-016-0717-7.
[26]
E. Noctor and F. Dunne, ‘Postnatal testing following gestational diabetes’, The Lancet Diabetes & Endocrinology, vol. 3, no. 10, pp. 761–762, Oct. 2015, doi: 10.1016/S2213-8587(15)00322-8.
[27]
K. I. Birkeland, ‘Hyperglycaemia in pregnancy: still a lot to learn’, The Lancet Diabetes & Endocrinology, vol. 3, no. 10, pp. 752–753, Oct. 2015, doi: 10.1016/S2213-8587(15)00282-X.
[28]
Rinki Murphy, ‘Monogenic diabetes and pregnancy’, Obstetric Medicine, vol. 8, no. 3, 2015, doi: doi: 10.1177/1753495X15590713. [Online]. Available: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4935018/
[29]
Z. A. Stewart et al., ‘Closed-Loop Insulin Delivery during Pregnancy in Women with Type 1 Diabetes’, New England Journal of Medicine, vol. 375, no. 7, pp. 644–654, Aug. 2016, doi: 10.1056/NEJMoa1602494.
[30]
‘Diabetes in pregnancy: management of diabetes and its complications from preconception to the postnatal period (NG3’. [Online]. Available: https://www.nice.org.uk/guidance/ng3
[31]
A. G. Jones and A. T. Hattersley, ‘The clinical utility of C-peptide measurement in the care of patients with diabetes’, Diabetic Medicine, vol. 30, no. 7, pp. 803–817, Jul. 2013, doi: 10.1111/dme.12159.
[32]
‘Unit 3 – Special care groups: A practical guide to pregnancy complicated by diabetes - Diabetes & Primary Care’. [Online]. Available: http://www.diabetesandprimarycare.co.uk/journal-content/view/unit-3-special-care-groups-a-practical-guide-to-pregnancy-complicated-by-diabetes/?preview
[33]
J. Brown et al., ‘Lifestyle interventions for the treatment of women with gestational diabetes’, in Cochrane Database of Systematic Reviews, Chichester, UK: John Wiley & Sons, Ltd, 1996 [Online]. Available: http://doi.wiley.com/10.1002/14651858.CD011970.pub2
[34]
B. Rasouli et al., ‘Serious life events and the risk of latent autoimmune diabetes in adults (LADA) and Type 2 diabetes’, Diabetic Medicine, vol. 34, no. 9, pp. 1259–1263, Sep. 2017, doi: 10.1111/dme.13410.
[35]
M. Davies, D. Dahl, T. Heise, J. Kiljanski, and C. Mathieu, ‘Introduction of biosimilar insulins in Europe’, Diabetic Medicine, vol. 34, no. 10, pp. 1340–1353, Oct. 2017, doi: 10.1111/dme.13400.
[36]
N. E. Perrin, M. J. Davies, N. Robertson, F. J. Snoek, and K. Khunti, ‘The prevalence of diabetes-specific emotional distress in people with Type 2 diabetes: a systematic review and meta-analysis’, Diabetic Medicine, vol. 34, no. 11, pp. 1508–1520, Nov. 2017, doi: 10.1111/dme.13448.
[37]
R. I. G. Holt, C. Cockram, A. Flyvbjerg, and B. J. Goldstein, Textbook of Diabetes, 5th ed. Somerset: John Wiley & Sons, Incorporated, 2016 [Online]. Available: http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056
[38]
R. I. G. Holt, Textbook of diabetes, 4th ed. Chichester: Wiley-Blackwell, 2010 [Online]. Available: http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=269077
[39]
‘Standards of Medical Care in Diabetes--2015: Summary of Revisions’, Diabetes Care, vol. 38, no. Supplement_1, pp. S4–S4, Jan. 2015, doi: 10.2337/dc15-S003.
[40]
‘A Randomised trial of the effect and cost-effectiveness of early intensive mulitfactorial therapy on 5-year cardiovascular outcomes in individuals with screen-detected type 2 diaberes:the anglod-Danish-Dutch Study of intensive Treatment in People with Screen-Detected Diabetes in Primary care (ADDITION-Europe) study.’ [Online]. Available: http://www.journalslibrary.nihr.ac.uk/hta/volume-20/issue-64#abstract
[41]
Kamlesh Khunti, ‘Systematic Review and Meta-Analysis of Response Rates and Diagnostic Yield of Screening for Type 2 Diabetes and Those at High Risk of Diabetes’, PLoS ONE, vol. 10, no. 9, 2015, doi: doi: 10.1371/journal.pone.0135702. [Online]. Available: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4556656/?report=classic
[42]
L. Tao et al., ‘Cost-effectiveness of intensive multifactorial treatment compared with routine care for individuals with screen-detected Type 2 diabetes: analysis of the ADDITION-UK cluster-randomized controlled trial’, Diabetic Medicine, vol. 32, no. 7, pp. 907–919, Jul. 2015, doi: 10.1111/dme.12711.
[43]
L. J. Gray, K. Khunti, E. G. Wilmot, T. Yates, and M. J. Davies, ‘External validation of two diabetes risk scores in a young UK South Asian population’, Diabetes Research and Clinical Practice, vol. 104, no. 3, pp. 451–458, Jun. 2014, doi: 10.1016/j.diabres.2014.03.018.
[44]
L. J. Gray et al., ‘Implementation of the automated Leicester Practice Risk Score in two diabetes prevention trials provides a high yield of people with abnormal glucose tolerance’, Diabetologia, vol. 55, no. 12, pp. 3238–3244, Dec. 2012, doi: 10.1007/s00125-012-2725-8.
[45]
S. E. Inzucchi et al., ‘Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes’, Diabetes Care, vol. 38, no. 1, pp. 140–149, Jan. 2015, doi: 10.2337/dc14-2441.
[46]
‘Guidelines’. [Online]. Available: https://www.idf.org/e-library/guidelines/79-global-guideline-for-type-2-diabetes
[47]
R. I. G. Holt, C. Cockram, A. Flyvbjerg, and B. J. Goldstein, Textbook of Diabetes, 5th ed. Somerset: John Wiley & Sons, Incorporated, 2016 [Online]. Available: http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056
[48]
R. I. G. Holt, Textbook of diabetes, 4th ed. Chichester: Wiley-Blackwell, 2010 [Online]. Available: http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=269077
[49]
R. I. G. Holt, Textbook of diabetes, 4th ed. Chichester: Wiley-Blackwell, 2010 [Online]. Available: http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=269077
[50]
M. J. Davies et al., ‘Effectiveness of the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cluster randomised controlled trial’, BMJ, vol. 336, no. 7642, pp. 491–495, Mar. 2008, doi: 10.1136/bmj.39474.922025.BE.
[51]
B. C. Johnston et al., ‘Comparison of Weight Loss Among Named Diet Programs in Overweight and Obese Adults’, JAMA, vol. 312, no. 9, Sep. 2014, doi: 10.1001/jama.2014.10397.
[52]
S. Steven et al., ‘Very Low-Calorie Diet and 6 Months of Weight Stability in Type 2 Diabetes: Pathophysiological Changes in Responders and Nonresponders’, Diabetes Care, vol. 39, no. 5, pp. 808–815, May 2016, doi: 10.2337/dc15-1942.
[53]
S. Steven and R. Taylor, ‘Restoring normoglycaemia by use of a very low calorie diet in long- and short-duration Type 2 diabetes’, Diabetic Medicine, vol. 32, no. 9, pp. 1149–1155, Sep. 2015, doi: 10.1111/dme.12722.
[54]
Amy Kennedy, ‘Does Exercise Improve Glycaemic Control in Type 1 Diabetes? A Systematic Review and Meta-Analysis’, PLoS ONE, vol. 8, no. 3, 2013, doi: doi: 10.1371/journal.pone.0058861. [Online]. Available: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3598953/
[55]
M. Chimen, A. Kennedy, K. Nirantharakumar, T. T. Pang, R. Andrews, and P. Narendran, ‘What are the health benefits of physical activity in type 1 diabetes mellitus? A literature review’, Diabetologia, vol. 55, no. 3, pp. 542–551, Mar. 2012, doi: 10.1007/s00125-011-2403-2.
[56]
D. Umpierre, ‘Physical Activity Advice Only or Structured Exercise Training and Association With HbA Levels in Type 2 Diabetes’, JAMA, vol. 305, no. 17, May 2011, doi: 10.1001/jama.2011.576.
[57]
L. Avery, D. Flynn, A. van Wersch, F. F. Sniehotta, and M. I. Trenell, ‘Changing Physical Activity Behavior in Type 2 Diabetes: A systematic review and meta-analysis of behavioral interventions’, Diabetes Care, vol. 35, no. 12, pp. 2681–2689, Dec. 2012, doi: 10.2337/dc11-2452.
[58]
V. W. Barry, M. Baruth, M. W. Beets, J. L. Durstine, J. Liu, and S. N. Blair, ‘Fitness vs. Fatness on All-Cause Mortality: A Meta-Analysis’, Progress in Cardiovascular Diseases, vol. 56, no. 4, pp. 382–390, Jan. 2014, doi: 10.1016/j.pcad.2013.09.002.
[59]
L. Qin, M. J. Knol, E. Corpeleijn, and R. P. Stolk, ‘Does physical activity modify the risk of obesity for type 2 diabetes: a review of epidemiological data’, European Journal of Epidemiology, vol. 25, no. 1, pp. 5–12, Jan. 2010, doi: 10.1007/s10654-009-9395-y.
[60]
I.-M. Lee, ‘Physical Activity and Weight Gain Prevention’, JAMA, vol. 303, no. 12, Mar. 2010, doi: 10.1001/jama.2010.312.
[61]
John M Jakicic, ‘Physical activity considerations for the treatment and prevention of obesity’, The American Journal of Clinical Nutrition, vol. 82, no. 1, pp. 226S-229S, Jan. 2005 [Online]. Available: http://ajcn.nutrition.org/content/82/1/226S
[62]
I. Heinonen et al., ‘Sedentary behaviours and obesity in adults: the Cardiovascular Risk in Young Finns Study’, BMJ Open, vol. 3, no. 6, May 2013, doi: 10.1136/bmjopen-2013-002901.
[63]
J. F. Sallis et al., ‘Progress in physical activity over the Olympic quadrennium’, The Lancet, vol. 388, no. 10051, pp. 1325–1336, Sep. 2016, doi: 10.1016/S0140-6736(16)30581-5.
[64]
J. S. Yeh, R. F. Kushner, and G. D. Schiff, ‘Obesity and Management of Weight Loss’, New England Journal of Medicine, vol. 375, no. 12, pp. 1187–1189, Sep. 2016, doi: 10.1056/NEJMclde1515935.
[65]
Henson, Joseph, ‘Associations of Sedentary Time with Fat Distribution in a High-Risk Population.’, Nov. 2014 [Online]. Available: https://lra.le.ac.uk/handle/2381/32505
[66]
The Eatwell Guide. Public Health England, 2016 [Online]. Available: https://www.gov.uk/government/publications/the-eatwell-guide
[67]
‘Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus (review) TA151, July 2008’. [Online]. Available: http://www.nice.org.uk/guidance/ta151
[68]
M. Hadjiconstantinou et al., ‘Do Web-Based Interventions Improve Well-Being in Type 2 Diabetes? A Systematic Review and Meta-Analysis’, Journal of Medical Internet Research, vol. 18, no. 10, Oct. 2016, doi: 10.2196/jmir.5991.
[69]
D. Young-Hyman, M. de Groot, F. Hill-Briggs, J. S. Gonzalez, K. Hood, and M. Peyrot, ‘Erratum. Psychosocial Care for People With Diabetes: A Position Statement of the American Diabetes Association. Diabetes Care 2016;39:2126–2140’, Diabetes Care, vol. 40, no. 2, p. 287.1-287, Feb. 2017, doi: 10.2337/dc17-er02.
[70]
M. Capehorn et al., ‘Challenges faced by physicians when discussing the Type 2 diabetes diagnosis with patients: insights from a cross-national study (IntroDia )’, Diabetic Medicine, Mar. 2017, doi: 10.1111/dme.13357.
[71]
Y. A. W. Hartman, H. J. Jansen, M. T. E. Hopman, C. J. Tack, and D. H. J. Thijssen, ‘Insulin-Associated Weight Gain in Type 2 Diabetes Is Associated With Increases in Sedentary Behavior’, Diabetes Care, vol. 40, no. 9, pp. e120–e121, Sep. 2017, doi: 10.2337/dc17-0787.
[72]
D. M. Hessler et al., ‘Diabetes distress is linked with worsening diabetes management over time in adults with Type 1 diabetes’, Diabetic Medicine, vol. 34, no. 9, pp. 1228–1234, Sep. 2017, doi: 10.1111/dme.13381.
[73]
M. Ferrari, M. Dal Cin, and M. Steele, ‘Self-compassion is associated with optimum self-care behaviour, medical outcomes and psychological well-being in a cross-sectional sample of adults with diabetes’, Diabetic Medicine, vol. 34, no. 11, pp. 1546–1553, Nov. 2017, doi: 10.1111/dme.13451.
[74]
William H. Polonsky,Lawrence Fisher,Jay Earles,R. James Dudl,Joel Lees,Joseph Mullan, ‘Assessing psychosocial distress in diabetes: development of the Diabetes Distress Scale’, Diabetes Care [Online]. Available: http://go.galegroup.com.ezproxy3.lib.le.ac.uk/ps/retrieve.do?tabID=T002&resultListType=RESULT_LIST&searchResultsType=SingleTab&searchType=AdvancedSearchForm&currentPosition=25&docId=GALE%7CA130282980&docType=Article&sort=Relevance&contentSegment=&prodId=EAIM&contentSet=GALE%7CA130282980&searchId=R15&userGroupName=leicester&inPS=true
[75]
‘Constructs of depression and distress in diabetes: time for an appraisal- ClinicalKey’. [Online]. Available: https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858715001357
[76]
R. I. G. Holt, C. Cockram, A. Flyvbjerg, and B. J. Goldstein, Textbook of Diabetes, 5th ed. Somerset: John Wiley & Sons, Incorporated, 2016 [Online]. Available: http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056
[77]
R. I. G. Holt, Textbook of diabetes, 4th ed. Chichester: Wiley-Blackwell, 2010 [Online]. Available: http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=269077
[78]
B. Gallwitz et al., ‘2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial’, The Lancet, vol. 380, no. 9840, pp. 475–483, Aug. 2012, doi: 10.1016/S0140-6736(12)60691-6.
[79]
C. V. Rizos, A. Kei, and M. S. Elisaf, ‘The current role of thiazolidinediones in diabetes management’, Archives of Toxicology, vol. 90, no. 8, pp. 1861–1881, Aug. 2016, doi: 10.1007/s00204-016-1737-4.
[80]
S. E. Nissen and K. Wolski, ‘Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes’, New England Journal of Medicine, vol. 356, no. 24, pp. 2457–2471, Jun. 2007, doi: 10.1056/NEJMoa072761.
[81]
M. Tanner, ‘Review: In type 2 diabetes, adding dipeptidyl peptidase-4 inhibitors to sulphonylureas increases hypoglycemia’, Annals of Internal Medicine, vol. 165, no. 4, Aug. 2016, doi: 10.7326/ACPJC-2016-165-4-020.
[82]
B. M. Mishriky, D. M. Cummings, and R. J. Tanenberg, ‘The efficacy and safety of DPP4 inhibitors compared to sulfonylureas as add-on therapy to metformin in patients with Type 2 diabetes: A systematic review and meta-analysis’, Diabetes Research and Clinical Practice, vol. 109, no. 2, pp. 378–388, Aug. 2015, doi: 10.1016/j.diabres.2015.05.025.
[83]
W. L. Bennett et al., ‘Comparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug Combinations’, Annals of Internal Medicine, vol. 154, no. 9, May 2011, doi: 10.7326/0003-4819-154-9-201105030-00336.
[84]
Merlin C. Thomas, ‘Systematic Literature Review of DPP-4 Inhibitors in Patients with Type 2 Diabetes Mellitus and Renal Impairment’, Diabetes Therapy, vol. 7, no. 3, 2016, doi: doi: 10.1007/s13300-016-0189-4. [Online]. Available: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5014795/
[85]
Paul Craddy, ‘Comparative Effectiveness of Dipeptidylpeptidase-4 Inhibitors in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison’, Diabetes Therapy, vol. 5, no. 1, 2014, doi: doi: 10.1007/s13300-014-0061-3. [Online]. Available: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4065303/
[86]
R. I. G. Holt, C. Cockram, A. Flyvbjerg, and B. J. Goldstein, Textbook of Diabetes, 5th ed. Somerset: John Wiley & Sons, Incorporated, 2016 [Online]. Available: http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056
[87]
R. I. G. Holt, Textbook of diabetes, 4th ed. Chichester: Wiley-Blackwell, 2010 [Online]. Available: http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=269077
[88]
B. Ryder et al., ‘ABCD position statement on GLP-1 based therapies and pancreatic damage’, Practical Diabetes, vol. 30, no. 9, pp. 388–391, Nov. 2013, doi: 10.1002/pdi.1816.
[89]
R. E. Amori, J. Lau, and A. G. Pittas, ‘Efficacy and Safety of Incretin Therapy in Type 2 Diabetes’, JAMA, vol. 298, no. 2, Jul. 2007, doi: 10.1001/jama.298.2.194.
[90]
J. B. Buse et al., ‘Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)’, The Lancet, vol. 374, no. 9683, pp. 39–47, Jul. 2009, doi: 10.1016/S0140-6736(09)60659-0.
[91]
‘Type 2 diabetes: prevention in people at high risk | Guidance and guidelines | NICE’ [Online]. Available: http://www.nice.org.uk/guidance/PH38
[92]
J. B. Buse et al., ‘DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks’, Diabetes Care, vol. 33, no. 6, pp. 1255–1261, Jun. 2010, doi: 10.2337/dc09-1914.
[93]
J. B. Buse et al., ‘Use of Twice-Daily Exenatide in Basal Insulin–Treated Patients With Type 2 Diabetes’, Annals of Internal Medicine, vol. 154, no. 2, Jan. 2011, doi: 10.7326/0003-4819-154-2-201101180-00300.
[94]
C. J. Bailey, J. L. Gross, A. Pieters, A. Bastien, and J. F. List, ‘Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial’, The Lancet, vol. 375, no. 9733, pp. 2223–2233, Jun. 2010, doi: 10.1016/S0140-6736(10)60407-2.
[95]
M. Diamant et al., ‘Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial’, The Lancet, vol. 375, no. 9733, pp. 2234–2243, Jun. 2010, doi: 10.1016/S0140-6736(10)60406-0.
[96]
M. A. Nauck, G. Meininger, D. Sheng, L. Terranella, and P. P. Stein, ‘Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial’, Diabetes, Obesity and Metabolism, vol. 9, no. 2, pp. 194–205, Mar. 2007, doi: 10.1111/j.1463-1326.2006.00704.x.
[97]
‘Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes | 1-Recommendations | Guidance and guidelines | NICE’ [Online]. Available: https://www.nice.org.uk/guidance/ta390/chapter/1-Recommendations
[98]
S. P. Marso et al., ‘Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes’, New England Journal of Medicine, Sep. 2016, doi: 10.1056/NEJMoa1607141.
[99]
M. A. Nauck and J. J. Meier, ‘The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions’, The Lancet Diabetes & Endocrinology, vol. 4, no. 6, pp. 525–536, Jun. 2016, doi: 10.1016/S2213-8587(15)00482-9.
[100]
‘Type 2 diabetes: lixisenatide | Evidence-review | Advice | NICE’ [Online]. Available: https://www.nice.org.uk/advice/esnm26/chapter/evidence-review
[101]
‘Dapagliflozin in combination therapy for treating type 2 diabetes June 2013’. [Online]. Available: http://www.nice.org.uk/guidance/ta288
[102]
‘Exenatide prolonged-release suspension for injection in combination with oral antidiabetic therapy for the treatment of type 2 diabetes | Guidance and guidelines TA 248 Feb 2015’. [Online]. Available: https://www.nice.org.uk/guidance/ta248
[103]
‘Liraglutide for the treatment of type 2 diabetes mellitus. TA203, Oct 2010’. [Online]. Available: https://www.nice.org.uk/guidance/ta203
[104]
S. P. Marso et al., ‘Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes’, New England Journal of Medicine, vol. 375, no. 4, pp. 311–322, Jul. 2016, doi: 10.1056/NEJMoa1603827.
[105]
‘Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes’, New England Journal of Medicine, vol. 375, no. 18, pp. 1797–1799, Nov. 2016, doi: 10.1056/NEJMc1611289.
[106]
C. Wanner et al., ‘Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes’, New England Journal of Medicine, vol. 375, no. 4, pp. 323–334, Jul. 2016, doi: 10.1056/NEJMoa1515920.
[107]
‘Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes’, New England Journal of Medicine, vol. 375, no. 18, pp. 1799–1802, Nov. 2016, doi: 10.1056/NEJMc1611290.
[108]
H. Courtney, R. Nayar, C. Rajeswaran, and R. Jandhyala, ‘Long-term management of type 2 diabetes with glucagon-like peptide-1 receptor agonists’, Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, vol. Volume 10, pp. 79–87, Mar. 2017, doi: 10.2147/DMSO.S126763.
[109]
J. B. Green et al., ‘Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes’, New England Journal of Medicine, vol. 373, no. 3, pp. 232–242, Jul. 2015, doi: 10.1056/NEJMoa1501352.
[110]
M. E. Rotz, V. S. Ganetsky, S. Sen, and T. F. Thomas, ‘Implications of incretin-based therapies on cardiovascular disease’, International Journal of Clinical Practice, vol. 69, no. 5, pp. 531–549, May 2015, doi: 10.1111/ijcp.12572.
[111]
S. P. Marso et al., ‘Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes’, New England Journal of Medicine, vol. 375, no. 4, pp. 311–322, Jul. 2016, doi: 10.1056/NEJMoa1603827.
[112]
P. A. Levin, H. Nguyen, E. Wittbrodt, and S. C. Kim, ‘Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research’, Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, vol. Volume 10, pp. 123–139, Apr. 2017, doi: 10.2147/DMSO.S130834.
[113]
R. I. G. Holt, C. Cockram, A. Flyvbjerg, and B. J. Goldstein, Textbook of Diabetes, 5th ed. Somerset: John Wiley & Sons, Incorporated, 2016 [Online]. Available: http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056
[114]
R. I. G. Holt, Textbook of diabetes, 4th ed. Chichester: Wiley-Blackwell, 2010 [Online]. Available: http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=269077
[115]
D. R. Leff and D. Heath, ‘Surgery for obesity in adulthood’, BMJ, vol. 339, no. sep22 1, pp. b3402–b3402, Sep. 2009, doi: 10.1136/bmj.b3402.
[116]
P. R. Schauer et al., ‘Bariatric Surgery versus Intensive Medical Therapy in Obese Patients with Diabetes’, New England Journal of Medicine, vol. 366, no. 17, pp. 1567–1576, Apr. 2012, doi: 10.1056/NEJMoa1200225.
[117]
M. C. Riddle et al., ‘Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin: A 24-week, randomized, placebo-controlled comparison (GetGoal-L)’, Diabetes Care, vol. 36, no. 9, pp. 2489–2496, Sep. 2013, doi: 10.2337/dc12-2454.
[118]
L. Sjöström et al., ‘Lifestyle, Diabetes, and Cardiovascular Risk Factors 10 Years after Bariatric Surgery’, New England Journal of Medicine, vol. 351, no. 26, pp. 2683–2693, Dec. 2004, doi: 10.1056/NEJMoa035622.
[119]
S. J. Persaud and P. M. Jones, ‘A Wake-up Call for Type 2 Diabetes?’, New England Journal of Medicine, vol. 375, no. 11, pp. 1090–1092, Sep. 2016, doi: 10.1056/NEJMcibr1607950.
[120]
J. A. Fagin and S. A. Wells, ‘Biologic and Clinical Perspectives on Thyroid Cancer’, New England Journal of Medicine, vol. 375, no. 11, pp. 1054–1067, Sep. 2016, doi: 10.1056/NEJMra1501993.
[121]
‘National Obesity Observatory’. [Online]. Available: http://www.noo.org.uk
[122]
P. R. Schauer et al., ‘Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 5-Year Outcomes’, New England Journal of Medicine, vol. 376, no. 7, pp. 641–651, Feb. 2017, doi: 10.1056/NEJMoa1600869.
[123]
S. H. Min, J.-H. Yoon, S. Hahn, and Y. M. Cho, ‘Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta-analysis’, Diabetes/Metabolism Research and Reviews, vol. 33, no. 1, Jan. 2017, doi: 10.1002/dmrr.2818.
[124]
K. M. Dungan et al., ‘Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial’, The Lancet, vol. 384, no. 9951, pp. 1349–1357, Oct. 2014, doi: 10.1016/S0140-6736(14)60976-4.
[125]
M. Nauck, R. S. Weinstock, G. E. Umpierrez, B. Guerci, Z. Skrivanek, and Z. Milicevic, ‘Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5)’, Diabetes Care, vol. 37, no. 8, pp. 2149–2158, Aug. 2014, doi: 10.2337/dc13-2761.
[126]
P. R. Schauer et al., ‘Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 5-Year Outcomes’, New England Journal of Medicine, vol. 376, no. 7, pp. 641–651, Feb. 2017, doi: 10.1056/NEJMoa1600869.
[127]
M. A. Bethel et al., ‘Assessing the Safety of Sitagliptin in Older Participants in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)’, Diabetes Care, vol. 40, no. 4, pp. 494–501, Apr. 2017, doi: 10.2337/dc16-1135.
[128]
R. I. G. Holt, C. Cockram, A. Flyvbjerg, and B. J. Goldstein, Textbook of Diabetes, 5th ed. Somerset: John Wiley & Sons, Incorporated, 2016 [Online]. Available: http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056
[129]
R. I. G. Holt, Textbook of diabetes, 4th ed. Chichester: Wiley-Blackwell, 2010 [Online]. Available: http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=269077
[130]
R. M. Bergenstal et al., ‘Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes’, New England Journal of Medicine, vol. 363, no. 4, pp. 311–320, Jul. 2010, doi: 10.1056/NEJMoa1002853.
[131]
P. Choudhary, N. R. Parrott, L. Birtles, and M. K. Rutter, ‘Islet cell transplantation: current status in the UK (2012)’, Practical Diabetes, vol. 29, no. 7, pp. 280–285, Sep. 2012, doi: 10.1002/pdi.1707.
[132]
J. C. Pickup, ‘Insulin-Pump Therapy for Type 1 Diabetes Mellitus’, New England Journal of Medicine, vol. 366, no. 17, pp. 1616–1624, Apr. 2012, doi: 10.1056/NEJMct1113948.
[133]
P. Srinivasan, G. C. Huang, S. A. Amiel, and N. D. Heaton, ‘Islet cell transplantation’, Postgraduate Medical Journal, vol. 83, no. 978, pp. 224–229, Apr. 2007, doi: 10.1136/pgmj.2006.053447.
[134]
‘Liraglutide for the treatment of type 2 diabetes mellitus. TA203, Oct 2010’. [Online]. Available: https://www.nice.org.uk/guidance/ta203
[135]
M. Villani, B. de Courten, and S. Zoungas, ‘Emergency treatment of hypoglycaemia: a guideline and evidence review’, Diabetic Medicine, vol. 34, no. 9, pp. 1205–1211, Sep. 2017, doi: 10.1111/dme.13379.
[136]
K. K. Dhatariya, C. Skedgel, and R. Fordham, ‘The cost of treating diabetic ketoacidosis in the UK: a national survey of hospital resource use’, Diabetic Medicine, vol. 34, no. 10, pp. 1361–1366, Oct. 2017, doi: 10.1111/dme.13427.
[137]
L. Leelarathna et al., ‘Comparison of different insulin pump makes under routine care conditions in adults with Type 1 diabetes’, Diabetic Medicine, vol. 34, no. 10, pp. 1372–1379, Oct. 2017, doi: 10.1111/dme.13412.
[138]
T. Yates and M. J. Davies, ‘Physical activity and Type 1 diabetes: an underused therapy’, Diabetic Medicine, vol. 34, no. 11, pp. 1498–1499, Nov. 2017, doi: 10.1111/dme.13445.
[139]
P. Narendran et al., ‘Exercise to preserve β-cell function in recent-onset Type 1 diabetes mellitus (EXTOD) - a randomized controlled pilot trial’, Diabetic Medicine, vol. 34, no. 11, pp. 1521–1531, Nov. 2017, doi: 10.1111/dme.13439.
[140]
R. I. G. Holt, C. Cockram, A. Flyvbjerg, and B. J. Goldstein, Textbook of Diabetes, 5th ed. Somerset: John Wiley & Sons, Incorporated, 2016 [Online]. Available: http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056
[141]
R. I. G. Holt, Textbook of diabetes, 4th ed. Chichester: Wiley-Blackwell, 2010 [Online]. Available: http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=269077
[142]
‘Exercise and Glucose Metabolism in Persons with Diabetes Mellitus: Perspectives on the Role for Continuous Glucose Monitoring’, Journal of diabetes science and technology (Online), vol. 3, no. 4 [Online]. Available: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2769951/
[143]
‘Minimizing Hypoglycemia in Diabetes: Table 1’, Diabetes Care, vol. 38, no. 8, pp. 1583–1591, Aug. 2015, doi: 10.2337/dc15-0279.
[144]
‘[ARCHIVED CONTENT] Medicines management: Everybody’s business : Department of Health - Publications and statistics’. [Online]. Available: http://webarchive.nationalarchives.gov.uk/20080205132320/http:/dh.gov.uk/en/publicationsandstatistics/publications/publicationspolicyandguidance/dh_082200
[145]
‘Medicines adherence: involving patients in decisions about prescribed medicines and supporting adherence. CG76, Jan 2009’. [Online]. Available: https://www.nice.org.uk/guidance/cg76
[146]
J. Grammes, W. Stock, C. G. Mann, E. M. Flynn, and T. Kubiak, ‘Focus group study to identify the central facets of fear of hypoglycaemia in people with Type 2 diabetes mellitus’, Diabetic Medicine, Aug. 2017, doi: 10.1111/dme.13506.
[147]
S. Sivasubramaniyam, S. A. Amiel, and P. Choudhary, ‘Proportion of daily capillary blood glucose readings required in the target range for target glycaemic control: shift of focus from target range to proportion in range’, Diabetic Medicine, vol. 34, no. 10, pp. 1456–1460, Oct. 2017, doi: 10.1111/dme.13438.
[148]
A. F. Vloemans et al., ‘Keeping safe. Continuous glucose monitoring (CGM) in persons with Type 1 diabetes and impaired awareness of hypoglycaemia: a qualitative study’, Diabetic Medicine, vol. 34, no. 10, pp. 1470–1476, Oct. 2017, doi: 10.1111/dme.13429.
[149]
I. Harman-Boehm, ‘Continuous glucose monitoring in type 2 diabetes’, Diabetes Research and Clinical Practice, vol. 82, pp. S118–S121, Dec. 2008, doi: 10.1016/j.diabres.2008.09.051.
[150]
Bailey, Stephen, Academic Writing : A Handbook for International Students. [Online]. Available: http://lib.myilibrary.com.ezproxy4.lib.le.ac.uk/Open.aspx?id=310467
[151]
P. Creme and M. R. Lea, Writing At University: A Guide For Students, 3rd ed. Maidenhead: McGraw-Hill Education, 2008 [Online]. Available: https://ebookcentral.proquest.com/lib/leicester/detail.action?pq-origsite=primo&docID=345134
